相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling
Peng Yang et al.
CELLULAR SIGNALLING (2014)
Combination of Gefitinib and DNA Methylation Inhibitor Decitabine Exerts Synergistic Anti-Cancer Activity in Colon Cancer Cells
Yun-feng Lou et al.
PLOS ONE (2014)
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as a Protein Kinase
Xueliang Gao et al.
MOLECULAR CELL (2012)
NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma
Wei Chen et al.
LIVER INTERNATIONAL (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Weiwei Yang et al.
NATURE CELL BIOLOGY (2012)
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells
Huan-Chih Chiu et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Weibo Luo et al.
CELL (2011)
Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model
Wenhao Guo et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Weiwei Yang et al.
NATURE (2011)
Clinical Impact of Phosphorylated Signal Transducer and Activator of Transcription 3, Epidermal Growth Factor Receptor, p53, and Vascular Endothelial Growth Factor Receptor I Expression in Resected Adenocarcinoma of Lung by Using Tissue Microarray
Hyeong Su Kim et al.
CANCER (2010)
A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance
Eric B. Haura et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
Jonna Nevo et al.
CLINICAL CANCER RESEARCH (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators
Hui-Wen Lo et al.
CLINICAL CANCER RESEARCH (2008)
Targeting the epidermal growth factor receptor in metastatic colorectal cancer
Kimmie Ng et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription
Jungwoon Lee et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase
Akemi Hoshino et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death
Attila Stetak et al.
CANCER RESEARCH (2007)
Pyruvate kinase type M2 and its role in tumor growth and spreading
S Mazurek et al.
SEMINARS IN CANCER BIOLOGY (2005)
Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis
JD Dombrauckas et al.
BIOCHEMISTRY (2005)
Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines
BC Yoo et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
分享论文
